Lexicon Pharmaceuticals (LXRX) Upgraded to “Hold” at BidaskClub
BidaskClub upgraded shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) from a sell rating to a hold rating in a report released on Thursday.
Several other research firms have also recently weighed in on LXRX. Gabelli cut Lexicon Pharmaceuticals from a hold rating to a sell rating in a report on Wednesday. Zacks Investment Research cut Lexicon Pharmaceuticals from a buy rating to a hold rating in a report on Friday, January 18th. ValuEngine raised Lexicon Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday. Wedbush increased their price target on Lexicon Pharmaceuticals from $36.00 to $38.00 and gave the company an outperform rating in a report on Monday, March 4th. Finally, Citigroup reissued a buy rating and set a $14.00 price target on shares of Lexicon Pharmaceuticals in a report on Tuesday, January 22nd. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of Hold and a consensus target price of $20.38.
LXRX stock traded up $0.27 during midday trading on Thursday, hitting $7.60. The company’s stock had a trading volume of 6,048 shares, compared to its average volume of 870,616. The stock has a market capitalization of $789.14 million, a PE ratio of -5.91 and a beta of 0.70. Lexicon Pharmaceuticals has a 12 month low of $4.26 and a 12 month high of $13.97.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in Lexicon Pharmaceuticals by 1.9% in the 3rd quarter. Vanguard Group Inc. now owns 3,834,766 shares of the biopharmaceutical company’s stock worth $40,917,000 after purchasing an additional 72,640 shares during the period. MetLife Investment Advisors LLC raised its holdings in Lexicon Pharmaceuticals by 49.8% in the 3rd quarter. MetLife Investment Advisors LLC now owns 35,705 shares of the biopharmaceutical company’s stock worth $381,000 after purchasing an additional 11,862 shares during the period. D.A. Davidson & CO. bought a new position in Lexicon Pharmaceuticals in the 4th quarter worth $87,000. Virtus ETF Advisers LLC raised its holdings in Lexicon Pharmaceuticals by 35.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 82,295 shares of the biopharmaceutical company’s stock worth $546,000 after purchasing an additional 21,567 shares during the period. Finally, Wedbush Securities Inc. raised its holdings in Lexicon Pharmaceuticals by 39.4% in the 4th quarter. Wedbush Securities Inc. now owns 174,442 shares of the biopharmaceutical company’s stock worth $1,158,000 after purchasing an additional 49,312 shares during the period. 99.34% of the stock is currently owned by hedge funds and other institutional investors.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.